Vanda Pharmaceuticals Inc. (Vanda), a biopharmaceutical company, focused on the development and commercialisation of products to treat central nervous system disorders, announced that four new Fanapt patents are now listed in the US Food and Drug Administration publication Approved Drug Products With Therapeutic Equivalence Evaluations, commonly known as the Orange Book.
Patent number 9,072,742 expires in January 2031. Patent number 9,074,254 expires in December 2031. Patent number 9,074,255 expires in December 2030. Patent number 9,074,256 expires in February 2031.
Prior to these newly listed patents, the Fanapt Orange Book listed patents were the US composition of matter patent, the '610 patent, the '776 patent and the '638 patent, expected to expire in November 2016, November 2027, August 2030 and October 2030, respectively.